Clinical trial

A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)

NCT03964207

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2019-11-25

PhasePHASE4

Study timeline

Study start (actual)2019-11-25Date precision: day

Registry last updated2023-10-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Pulmonary Disease, Chronic Obstructiveunresolved

Interventions

Tiotropium Respimat® (T1)DRUG

Tiotropium Handihaler® (T2)DRUG

Sponsors & collaborators

Boehringer Ingelheimlead sponsor

Mapped research locations

BeijingChina2 ShanghaiChina2 GuangzhouChina2 ChengduChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03964207 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.